De-Ning Ma

1.4k total citations
38 papers, 1.1k citations indexed

About

De-Ning Ma is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, De-Ning Ma has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in De-Ning Ma's work include Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (4 papers). De-Ning Ma is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (4 papers). De-Ning Ma collaborates with scholars based in China, Ethiopia and Saudi Arabia. De-Ning Ma's co-authors include Xiao‐Dong Zhu, Hui‐Chuan Sun, Zong‐Tao Chai, Hao Cai, Dongmei Gao, Chengdong Qin, Zhao–You Tang, Bo‐Gen Ye, Jian‐Yang Ao and Chenghao Wang and has published in prestigious journals such as PLoS ONE, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

De-Ning Ma

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
De-Ning Ma China 17 558 416 224 216 116 38 1.1k
Haijian Zhang China 18 579 1.0× 335 0.8× 111 0.5× 148 0.7× 138 1.2× 51 828
Wendy W. Hwang‐Verslues Taiwan 17 818 1.5× 424 1.0× 195 0.9× 546 2.5× 103 0.9× 22 1.4k
Yunhe Liu China 19 438 0.8× 164 0.4× 167 0.7× 246 1.1× 105 0.9× 51 1.1k
Beverly L. Falcón United States 16 804 1.4× 339 0.8× 110 0.5× 435 2.0× 216 1.9× 34 1.4k
Caner Ercan Switzerland 12 536 1.0× 373 0.9× 98 0.4× 175 0.8× 310 2.7× 24 906
Xiaoliang Xu China 18 528 0.9× 367 0.9× 113 0.5× 134 0.6× 86 0.7× 39 862
Ning Liu China 20 428 0.8× 148 0.4× 159 0.7× 242 1.1× 156 1.3× 97 1.0k
Jian Kong China 19 433 0.8× 345 0.8× 151 0.7× 175 0.8× 100 0.9× 37 1.0k
Yan‐Miao Huo China 21 559 1.0× 435 1.0× 276 1.2× 534 2.5× 184 1.6× 54 1.2k
Ling–Qun Kong China 19 586 1.1× 411 1.0× 489 2.2× 448 2.1× 139 1.2× 23 1.3k

Countries citing papers authored by De-Ning Ma

Since Specialization
Citations

This map shows the geographic impact of De-Ning Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by De-Ning Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites De-Ning Ma more than expected).

Fields of papers citing papers by De-Ning Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by De-Ning Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by De-Ning Ma. The network helps show where De-Ning Ma may publish in the future.

Co-authorship network of co-authors of De-Ning Ma

This figure shows the co-authorship network connecting the top 25 collaborators of De-Ning Ma. A scholar is included among the top collaborators of De-Ning Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with De-Ning Ma. De-Ning Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shao, Yong, et al.. (2025). Neoadjuvant therapy for resectable colorectal cancer pulmonary oligometastases: a retrospective cohort study. International Journal of Colorectal Disease. 40(1). 191–191.
3.
4.
Gao, Xinyi, et al.. (2023). Upregulation of HMGB1 in tumor-associated macrophages induced by tumor cell-derived lactate further promotes colorectal cancer progression. Journal of Translational Medicine. 21(1). 53–53. 36 indexed citations
5.
Qin, Chengdong, Siyuan Liu, Shiqi Zhou, et al.. (2023). Tanshinone IIA promotes vascular normalization and boosts Sorafenib’s anti-hepatoma activity via modulating the PI3K-AKT pathway. Frontiers in Pharmacology. 14. 1189532–1189532. 9 indexed citations
6.
Qin, Chengdong, Siyuan Liu, Xianghou Xia, et al.. (2023). PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. Frontiers in Immunology. 14. 1114572–1114572. 3 indexed citations
7.
Wang, Meng, De-Ning Ma, Weiyuan Zhang, et al.. (2022). Short-term and long-term outcomes of natural orifice specimen extraction surgeries (NOSES) in rectal cancer: a comparison study of NOSES and non-NOSES. Annals of Translational Medicine. 10(8). 488–488. 6 indexed citations
8.
Ma, De-Ning, et al.. (2020). <p>Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers</p>. OncoTargets and Therapy. Volume 13. 6927–6935. 22 indexed citations
9.
10.
Zhu, Weiping, Yiming Zhao, Xigan He, et al.. (2018). Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma. Cell Death and Disease. 9(2). 69–69. 16 indexed citations
11.
Cao, Manqing, A‐Bin You, Xiao‐Dong Zhu, et al.. (2018). miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. Journal of Hematology & Oncology. 11(1). 12–12. 177 indexed citations
12.
Qin, Chengdong, De-Ning Ma, Shi-Zhe Zhang, et al.. (2018). The Rho GTPase Rnd1 inhibits epithelial–mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. Cell Death and Disease. 9(5). 486–486. 21 indexed citations
13.
14.
Ao, Jian‐Yang, Xiao‐Dong Zhu, Zong‐Tao Chai, et al.. (2017). Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 16(8). 1544–1554. 153 indexed citations
15.
Chen, Shuying, De-Ning Ma, Jingjun Zhang, et al.. (2017). MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma. Journal of Cancer. 8(4). 617–625. 29 indexed citations
16.
Qin, Chengdong, De-Ning Ma, Zhenggang Ren, et al.. (2017). Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway. Oncology Reports. 37(3). 1725–1735. 43 indexed citations
17.
Lv, Fang, Yang Meng, De-Ning Ma, et al.. (2017). Association between bone mineral density, muscle strength, and vitamin D status in patients with myasthenia gravis: a cross-sectional study. Osteoporosis International. 28(8). 2383–2390. 12 indexed citations
18.
Ma, De-Ning, Zheng Zhang, Yushang Cui, et al.. (2016). Long-term outcomes of 47 patients with aggressive fibromatosis of the chest treated with surgery. European Journal of Surgical Oncology. 42(11). 1693–1698. 9 indexed citations
19.
Zhu, Weiping, Yiming Zhao, Jiamin Zhou, et al.. (2016). Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial-mesenchymal transition. Journal of Hematology & Oncology. 9(1). 127–127. 43 indexed citations
20.
Zhu, Weiping, De-Ning Ma, Mingrong Cheng, et al.. (2016). Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. Oncology Reports. 36(2). 845–852. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haijian Zhang Breakdown of academic impact, for papers by Wendy W. Hwang‐Verslues Breakdown of academic impact, for papers by Yunhe Liu Breakdown of academic impact, for papers by Beverly L. Falcón Breakdown of academic impact, for papers by Caner Ercan Breakdown of academic impact, for papers by Xiaoliang Xu Breakdown of academic impact, for papers by Ning Liu Breakdown of academic impact, for papers by Jian Kong Breakdown of academic impact, for papers by Yan‐Miao Huo Breakdown of academic impact, for papers by Ling–Qun Kong
Rankless by CCL
2026